生产企业：Armata Pharmaceuticals, Inc.
AP-PA02 is an inhaled bacteriophage product candidate developed by Armata Pharmaceuticals, Inc. that has completed Phase 2 clinical studies in cystic fibrosis (CF) and non-CF bronchiectasis (NCFB) patients with chronic pulmonary Pseudomonas aeruginosa infection.
AP-PA02 is an inhaled bacteriophage product candidate developed by Armata Pharmaceuticals, Inc. that has completed Phase 2 clinical studies in cystic fibrosis (CF) and non-CF bronchiectasis (NCFB) patients with chronic pulmonary Pseudomonas aeruginosa infection.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
